Shane Ward
Chief Operating Officer bei CIDARA THERAPEUTICS, INC.
Vermögen: 293 268 $ am 31.03.2024
Profil
Shane M.
Ward's current job is as the COO, Chief Legal Officer & Secretary at Cidara Therapeutics, Inc. Formerly, Mr. Ward worked as a Senior Counsel at Abbott Laboratories from 2003 to 2006, as a Senior Attorney at Gilead Sciences, Inc. from 2003 to 2006, as an Associate General Counsel at Human Genome Sciences, Inc. in 2010, as the VP-Compliance & Associate General Counsel at Dynavax Technologies Corp.
from 2012 to 2015, as the Chief Legal & Strategy Officer at Bellicum Pharmaceuticals, Inc. from 2018 to 2020, as the Senior Vice President & General Counsel at Versartis, Inc. from 2015 to 2018, and as an Associate at Sidley Austin LLP from 2001 to 2003.
Mr. Ward obtained an undergraduate degree from the University of Virginia and a graduate degree from Georgetown University Law Center.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.03.2024 | 318 770 ( 0,35% ) | 293 268 $ | 31.03.2024 |
Aktive Positionen von Shane Ward
| Unternehmen | Position | Beginn |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | Chief Operating Officer | 30.09.2022 |
Ehemalige bekannte Positionen von Shane Ward
| Unternehmen | Position | Ende |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | General Counsel | 01.11.2020 |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Compliance Officer | - |
| DYNAVAX TECHNOLOGIES CORPORATION | Compliance Officer | 01.03.2015 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01.01.2010 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01.01.2006 |
Ausbildung von Shane Ward
| University of Virginia | Undergraduate Degree |
| Georgetown University Law Center | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| CIDARA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Sidley Austin LLP
 Sidley Austin LLP Miscellaneous Commercial ServicesCommercial Services Sidley Austin LLP is a premier legal adviser with over 2000 lawyers in 20 offices worldwide. Sidley Austin is based in Chicago, IL and has subsidiaries in Germany, Hong Kong, United States, United Kingdom, and Japan. The firm has been providing superior client service for over 150 years and has a diverse group of legal professionals from many cultures who are dedicated to teamwork and collaboration. Sidley Austin has forged enduring relationships with the business community and serves a varied and high-caliber group of market leaders, many of whom are pioneers in their respective industries and professions. The firm is committed to pro bono service and its lawyers and staff devote more than 100,000 hours annually to serving those most in need. | Commercial Services |
